Disease severity in moderate-to-severe plaque psoriasis: results from the Belgian REDISCOVER study

被引：0
|
作者：
Hillary, Tom [1 ]
Ghys, Liesbeth [2 ]
Willaert, Fabienne [3 ]
Swimberghe, Sandra
Lecuyer, Myriam
Ghislain, Pierre-Dominique [4 ]
Morrens, Joachim [2 ]
Lambert, Jo [5 ]
机构：
[1] Univ Hosp Leuven, Leuven, Belgium
[2] Abbvie Belgium, Brussels, Belgium
[3] Univ Libre Bruxelles, Erasme Hosp, Dermatol, Brussels, Belgium
[4] Catholic Univ Louvain, Dermatol, Clin St Luc, Brussels, Belgium
[5] Ghent Univ Hosp, Dermatol, Ghent, Belgium
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2023年 / 89卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
40351
引用
收藏
页码：AB37 / AB37
页数：1
相关论文
共 50 条
  • [31] Tildrakizumab for Moderate-to-Severe Chronic Plaque Psoriasis: a Review of the Literature
    Schrom, Kory P.
    Bitterman, Avi
    Korman, Neil J.
    CURRENT DERMATOLOGY REPORTS, 2019, 8 (01) : 6 - 13
  • [32] Clinical Utility of Guselkumab in the Treatment of Moderate-to-Severe Plaque Psoriasis
    Light, Jeremy G.
    Su, Jennifer J.
    Feldman, Steven R.
    CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY, 2021, 14 : 55 - 63
  • [33] Therapeutic Inertia in the Management of Moderate-to-Severe Plaque Psoriasis in Adolescents
    Melin, Audrey
    Sei, Jean-Francois
    Corgibet, Florence
    Nicolas, Cristele
    Maghia, Remi
    Halioua, Bruno
    Beauchet, Alain
    Mahe, Emmanuel
    ACTA DERMATO-VENEREOLOGICA, 2021, 101
  • [34] Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis
    Gisondi, P.
    Altomare, G.
    Ayala, F.
    Bardazzi, F.
    Bianchi, L.
    Chiricozzi, A.
    Costanzo, A.
    Conti, A.
    Dapavo, P.
    De Simone, C.
    Foti, C.
    Naldi, L.
    Offidani, A.
    Parodi, A.
    Piaserico, S.
    Prignano, F.
    Rongioletti, F.
    Stingeni, L.
    Talamonti, M.
    Girolomoni, G.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 (05) : 774 - 790
  • [35] Ustekinumab: Treatment of Adult Moderate-to-Severe Chronic Plaque Psoriasis
    Scanlon, James V.
    Exter, Benjamin P.
    Steinberg, Michael
    Jarvis, Courtney I.
    ANNALS OF PHARMACOTHERAPY, 2009, 43 (09) : 1456 - 1465
  • [36] Polymorphisms associated with etanercept response in moderate-to-severe plaque psoriasis
    Ovejero-Benito, Maria C.
    Prieto-Perez, Rocio
    Llamas-Velasco, Mar
    Belmonte, Carmen
    Cabaleiro, Teresa
    Roman, Manuel
    Ochoa, Dolores
    Talegon, Maria
    Saiz-Rodriguez, Miriam
    Dauden, Esteban
    Abad-Santos, Francisco
    PHARMACOGENOMICS, 2017, 18 (07) : 631 - 638
  • [37] Clinical and economic review of secukinumab for moderate-to-severe plaque psoriasis
    Wong, Ian T. Y.
    Shojania, Kam
    Dutz, Jan
    Tsao, Nicole W.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2016, 16 (02) : 153 - 166
  • [38] Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis
    Leman, J.
    Burden, A. D.
    BRITISH JOURNAL OF DERMATOLOGY, 2012, 167 : 12 - 20
  • [39] Pharmacodynamic assessment of apremilast for the treatment of moderate-to-severe plaque psoriasis
    Bianchi, Luca
    Del Duca, Ester
    Romanelli, Marco
    Saraceno, Rosita
    Chimenti, Sergio
    Chiricozzi, Andrea
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2016, 12 (09) : 1121 - 1128
  • [40] Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
    Gordon, K. B.
    Blauvelt, A.
    Papp, K. A.
    Langley, R. G.
    Luger, T.
    Ohtsuki, M.
    Reich, K.
    Amato, D.
    Ball, S. G.
    Braun, D. K.
    Cameron, G. S.
    Erickson, J.
    Konrad, R. J.
    Muram, T. M.
    Nickoloff, B. J.
    Osuntokun, O. O.
    Secrest, R. J.
    Zhao, F.
    Mallbris, L.
    Leonardi, C. L.
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (04): : 345 - 356
12345